会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • PREVENTION OF AGGREGATION OF IMMUNOGLOBULIN LIGHT OR HEAVY CHAINS
    • 防止聚集免疫球蛋白轻链或重链
    • WO2008052933A3
    • 2008-11-13
    • PCT/EP2007061514
    • 2007-10-26
    • DOMANTIS LTDDE WILDT RUDOLF M TJAMES LEO CJONES PHILIP CSCHON OLIVERWINTER GREGORY PAUL
    • DE WILDT RUDOLF M TJAMES LEO CJONES PHILIP CSCHON OLIVERWINTER GREGORY PAUL
    • C07K16/42C07K7/00C07K14/315C07K16/22C07K16/24C12N15/12C12N15/63
    • C07K16/22C07K16/241C07K16/42C07K2317/31C07K2317/567C07K2317/569
    • The present invention provides an inhibitor of the aggregation of immunoglobulin chains (or immunoglobulin VL or CHl domains). In preferred embodiments, the inhibitor comprises or consists of a polypeptide which comprises or consists of (a) an amino acid sequence corresponding to the amino acid sequence of the FRl region of an immunoglobulin light chain variable domain, or part thereof which includes amino acid residue 12, (b) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of bacterial superantigen Protein L, or part thereof, and/or (c) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of streptococcal protein G (SpG), or part thereof, or a variant, fusion or derivative thereof, or a fusion of a said variant or derivative thereof which retains the ability of the parent polypeptide to inhibit aggregation of immunoglobulin chains, or domains thereof. The invention further provides a non-naturally occurring antibody, or antigen-binding fragment, fusion or derivative thereof comprising a light chain variable domain, or a fusion of a said fragment or derivative, wherein the FRl region of the light chain variable domain is modified (e.g. mutated) so as to inhibit, at least in part, the ability of the antibody, fragment, fusion or derivative to form aggregates. Most preferably, the light chain variable domain is modified at position 12 of the FR1 region by replacing the naturally occurring amino acid (e.g. serine in ? light chains) with proline.
    • 本发明提供免疫球蛋白链(或免疫球蛋白VL或CH1结构域)聚集的抑制剂。 在优选的实施方案中,抑制剂包含或由多肽组成,该多肽包含(a)对应于免疫球蛋白轻链可变结构域的FR1区的氨基酸序列的氨基酸序列或其部分,其部分包括氨基酸残基 12,(b)对应于细菌超抗原蛋白L的免疫球蛋白结合结构域的氨基酸序列或其部分的氨基酸序列,和/或(c)对应于免疫球蛋白的氨基酸序列的氨基酸序列 链球菌蛋白G(SpG)或其部分或其变体,融合物或衍生物或其所述变体或衍生物的融合物的结合结构域,其保留母体多肽抑制免疫球蛋白链的聚集的能力,或 其领域。 本发明还提供非天然存在的抗体或其抗原结合片段,其融合物或衍生物,其包含轻链可变区或所述片段或衍生物的融合物,其中轻链可变结构域的FR1区域被修饰 (例如突变),以至少部分地抑制抗体,片段,融合物或衍生物形成聚集体的能力。 最优选地,通过用脯氨酸替代天然存在的氨基酸(例如轻链中的丝氨酸),轻链可变结构域在FR1区的第12位被修饰。